

- Collen MF, Dales LC, Friedman GD, et al. Multiphasic checkup evaluation study. 4. Preliminary cost benefit analysis for middle-aged men. *Prev Med* 1973;2:236–246.
- Prorok PC, Kramer BS, Gohagan JK. Screening theory and study design: the basics. In: Kramer B, Prorok P, eds. *Cancer Screening*. New York: Marcel Dekker; 1999:29–53.
- Welch HG, Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst* 2010;102:605–613.
- Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. *J Clin Oncol* 1995;13:2033–2038.
- Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. *N Engl J Med* 2002;346:1041–1046.
- Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. *J Chronic Dis* 1986;39:453–463.
- Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. *Am J Epidemiol* 2007;165:874–881.
- Boyle P, Brawley OW. Prostate cancer: current evidence weighs against population screening. *CA Cancer J Clin* 2009;59:220–224.
- Autier P, Boyle P, Buyse M, et al. Is FOB screening really the answer for lowering mortality in colorectal cancer? *Recent Results Cancer Res* 2003;163:254–263.
- de Boer AG, Taskila T, Ojajarvi A, et al. Cancer survivors and unemployment: a meta-analysis and meta-regression. *JAMA* 2009;301:753–762.
- Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
- Eden J, Levit L, Berg A, et al., eds. *Finding What Works in Health Care: Standards for Systematic Reviews*. Washington DC: The National Academies Press; 2011.
- Graham R, Mancher M, Wolman DM, et al. *Medicine CoSfDTCPGlo*. Washington, DC: The National Academies; 2011.
- Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2012;157:120–134.
- Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. *JAMA* 2011;306:2495–2499.
- Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. *Health Insurance Plan. J Natl Cancer Inst Monogr* 1997:27–30.
- Miller AB, Wall C, Baines CJ, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. *BMJ* 2014;348:g366.
- Tabar L, Fagerberg G, Duffy SW, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. *Radiol Clin North Am* 1992;30:187–210.
- Moy L, Slanetz PJ, Moore R, et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. *Radiology* 2002;225:176–181.
- Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. *Eur J Cancer* 2007;43:1905–1917.
- Wishart GC, Campisi M, Boswell M, et al. The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. *Eur J Surg Oncol* 2010;36:535–540.
- Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. *J Natl Cancer Inst* 2001;93:1624–1632.
- Autier P, Boniol M, Middleton R, et al. Advanced breast cancer incidence following population-based mammographic screening. *Ann Oncol* 2011;22:1726–1735.
- Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med* 2012;367:1998–2005.
- Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer* 2013;108:2205–2240.
- Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med* 2005;353:1784–1792.
- Harris R, Yeatts J, Kinsinger L. Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. *Prev Med* 2011;53:108–114.
- Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med* 2009;151:727–737.
- Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. *Ann Intern Med* 2009;151:738–747.
- U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2009;151:716–726.
- Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. *Ann Intern Med* 2012;156:635–648.
- Barnett GC, Shah M, Redman K, et al. Risk factors for the incidence of breast cancer: do they affect survival from the disease? *J Clin Oncol* 2008;26:3310–3316.
- Gierach GL, Ichikawa L, Kerlikowske K, et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. *J Natl Cancer Inst* 2012;104:1218–1227.
- Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. *JAMA* 2008;299:2151–2163.
- Garthner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. *Cochrane Database Syst Rev* 2013;4:CD009632.
- Tice JA, O'Meara ES, Weaver DL, et al. Benign breast disease, mammographic breast density, and the risk of breast cancer. *J Natl Cancer Inst* 2013;105:1043–1049.
- Kerlikowske K, Hubbard RA, Miglioretti DL, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. *Ann Intern Med* 2011;155:493–502.
- Haas BM, Kalra V, Geisel J, et al. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. *Radiology* 2013;269:694–700.
- Rosenberg RD, Yankaskas BC, Abraham LA, et al. Performance benchmarks for screening mammography. *Radiology* 2006;241:55–66.
- Gomez SL, Lichtensztajn D, Kurian AW, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. *J Clin Oncol* 2010;28:e155–e157.
- Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. *J Clin Oncol* 2009;27:1362–1367.
- Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. *Radiology* 1998;209:511–518.
- Kerlikowske K, Grady D, Barclay J, et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography. *JAMA* 1996;276:33–38.
- Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. *J Natl Cancer Inst* 1999;91:2020–2028.
- Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. *Breast Cancer Res* 2005;7:21–32.
- Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). *BMJ* 2012;345:e5660.
- Qaseem A, Snow V, Sherif K, et al. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2007;146:511–515.
- Tonelli M, Connor Gorber S, Joffres M, et al. Recommendations on screening for breast cancer in average-risk women aged 40–74 years. *CMAJ* 2011;183:1991–2001.
- Recommendations on cancer screening in the European Union. Advisory Committee on Cancer Prevention. *Eur J Cancer* 2000;36:1473–1478.
- Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57:75–89.
- Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med* 2000;343:1603–1607.
- Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013;369:1095–1105.
- Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med* 2012;366:2345–2357.
- Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med* 1993;328:1365–1371.
- Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. *J Natl Cancer Inst* 1999;91:434–437.
- Harcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet* 1996;348:1472–1477.
- Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996;348:1467–1471.
- Ahliquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. *JAMA* 1993;269:1262–1267.
- Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. *CA Cancer J Clin* 2003;53:44–55.

60. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet* 2010;375:1624–1633.
61. Levin TR. Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted? *Gastroenterol Clin North Am* 2002;31:1015–1029.
62. Littlejohn C, Hilton S, Macfarlane GJ, et al. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. *Br J Surg* 2012;99:1488–1500.
63. Elmunzer BJ, Hayward RA, Schoenfeld PS, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2012;9:e1001352.
64. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol* 2006;101:343–350.
65. Rosman AS, Korsten MA. Meta-analysis comparing CT colonography, air contrast barium enema, and colonoscopy. *Am J Med* 2007;120:203–210.
66. Imperiale TF, Wagner DR, Lin CY, et al. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. *Ann Intern Med* 2003;139:959–965.
67. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2008;149:627–637.
68. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. *Gastroenterology* 2003;124:544–560.
69. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. *N Engl J Med* 2012;366:697–706.
70. Murakami R, Tsukuma H, Ubukata T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. *Cancer* 1990;65:1255–1260.
71. Kampschoer GH, Fujii A, Masuda Y. Gastric cancer detected by mass survey. Comparison between mass survey and outpatient detection. *Scand J Gastroenterol* 1989;24:813–817.
72. Stael von Holstein C, Eriksson S, Hult B, et al. Endoscopic screening during 17 years for gastric stump carcinoma. A prospective clinical trial. *Scand J Gastroenterol* 1991;26:1020–1026.
73. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. *N Engl J Med* 2013;369:1106–1114.
74. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. *Hepatology* 2000;32:842–846.
75. Chalasani N, Horlander JC Sr, Said A, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. *Am J Gastroenterol* 1999;94:2988–2993.
76. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. *Hepatology* 1995;22:432–438.
77. Dodd GD 3rd, Miller WJ, Baron RL, et al. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. *AJR Am J Roentgenol* 1992;159:727–733.
78. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. *Lancet* 1987;1:1247–1249.
79. Christopherson WM, Lundin FE Jr, Mendez WM, et al. Cervical cancer control: a study of morbidity and mortality trends over a twenty-one-year period. *Cancer* 1976;38:1357–1366.
80. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. *Am J Public Health* 1995;85:791–794.
81. Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. *N Engl J Med* 2003;349:1501–1509.
82. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. *N Engl J Med* 2009;360:1385–1394.
83. Vesco KK, Whitlock EP, Eder M, et al. In: *Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force*. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
84. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA* 2002;287:2114–2119.
85. Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. *Int J Gynecol Pathol* 2013;32:76–115.
86. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998;338:423–428.
87. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. *J Natl Cancer Inst* 1999;91:252–258.
88. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. *Cancer Epidemiol Biomarkers Prev* 2003;12:485–490.
89. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. *Obstet Gynecol* 1998;92:727–735.
90. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. *Am J Obstet Gynecol* 2003;188:1406–1412.
91. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. *Am J Obstet Gynecol* 2003;188:1401–1405.
92. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. *N Engl J Med* 2007;357:1579–1588.
93. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin* 2012;62:147–172.
94. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. *Lancet* 2007;370:398–406.
95. Szarewski A. Cervical screening by visual inspection with acetic acid. *Lancet* 2007;370:365–366.
96. Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. *Gynecol Oncol* 2008;110:383–389.
97. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. *Int J Gynecol Cancer* 2005;15:679–691.
98. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. *J Clin Pathol* 2005;58:308–312.
99. Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. *Am J Obstet Gynecol* 2005;192:1214–1221.
100. Kobayashi E, Ueda Y, Matsuzaki S, et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2012;21:1902–1912.
101. Ren J, Cai H, Li Y, et al. Tumor markers for early detection of ovarian cancer. *Expert Rev Mol Diagn* 2010;10:787–798.
102. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control Clin Trials* 2000;21:273S–309S.
103. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA* 2011;305:2295–2303.
104. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol* 2009;10:327–340.
105. Drescher CW, Shah C, Thorpe J, et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. *J Clin Oncol* 2013;31:387–392.
106. Sharma A, Apostolidou S, Burnell M, et al. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). *Ultrasound Obstet Gynecol* 2012;40:338–344.
107. Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med* 2012;157:900–904.
108. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. *JAMA* 1995;273:491–497.
109. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001—testing for early lung cancer detection. *CA Cancer J Clin* 2001;51:38–75.
110. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary non-polyposis colon cancer. Cancer Genetics Studies Consortium. *JAMA* 1997;277:915–919.
111. Gull B, Karlsson B, Milsom I, et al. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. *Am J Obstet Gynecol* 2003;188:401–408.
112. Scamman CL. Follow-up study of lung cancer suspects in a mass chest X-ray survey. *N Engl J Med* 1951;244:541–544.
113. Cresswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. *Semin Oncol* 2010;37:202–215.
114. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. *Am Rev Respir Dis* 1984;130:561–565.
115. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. *Cancer* 1991;67:1155–1164.
116. Marcus PM, Bergstralh EJ, Zweig MH, et al. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. *J Natl Cancer Inst* 2006;98:748–756.

117. Manser R, Wright G, Hart D, et al. Surgery for early stage non-small cell lung cancer. *Cochrane Database Syst Rev* 2005;CD004699.
118. Kubik A, Parkin DM, Khat M, et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. *Int J Cancer* 1990; 45:26–33.
119. Oken MM, Hocking WC, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. *JAMA* 2011;306:1865–1873.
120. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. *N Engl J Med* 2013; 369:245–254.
121. Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. *Cancer* 2000;89:2363–2368.
122. Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. *JAMA Intern Med* 2014;174:269–274.
123. Ma J, Ward EM, Smith R, et al. Annual number of lung cancer deaths potentially avertable by screening in the United States. *Cancer* 2013;119: 1381–1385.
124. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin* 2013;63:107–117.
125. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA* 2012;307:2418–2429.
126. Montie JE, Smith JA. Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D. *Urology* 2004;63:207–209.
127. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA* 2005;293:2095–2101.
128. Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. *J Gen Intern Med* 2008;23:1809–1814.
129. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. *J Natl Cancer Inst* 2006;98:1128–1133.
130. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. *N Engl J Med* 2004;350:2239–2246.
131. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. *JAMA* 2005;294:66–70.
132. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. *Lancet* 2009;373:301–308.
133. Bill-Axelsson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2011;364: 1708–1717.
134. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 2012;367:203–213.
135. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. *J Natl Cancer Inst* 2012;104:125–132.
136. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320–1328.
137. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. *N Engl J Med* 2012;366:981–990.
138. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPEC. *Int J Cancer* 2010;126:2387–2393.
139. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol* 2010;11:725–732.
140. Kilpelainen TP, Tammela TL, Malila N, et al. Prostate cancer mortality in the Finnish randomized screening trial. *J Natl Cancer Inst* 2013;105: 719–725.
141. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol* 2012;61:1079–1092.
142. Boyle P. Screening for prostate cancer: have you had your cholesterol measured? *BJU Int* 2003;92:191–199.
143. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. *J Urol* 2009;182:2232–2241.
144. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin* 2010;60:70–98.
145. Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. *BJU Int* 2013;112:543–547.
146. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2009;150: 194–198.
147. Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. *Cancer* 2012;118:5395–5402.
148. Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. *J Am Acad Dermatol* 2012;66:201–211.
149. Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. *CA Cancer J Clin* 2013;63:88–105.
150. U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2009;150: 188–193.